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1    Introduction
The human papillomavirus (HPV) causes the most
common sexual transmitted infection (STI) of viral
aetiology.  At least 70 types of HPV are known to infect
the anogenital region.  Low-risk types (6, 11) are re-
sponsible for rather benign conditions like genital warts,
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Abstract
Aim: To investigate whether urine is a good medium for screening and whether there is a correlation between the
amount of extracted DNA and human papillomavirus (HPV)-positivity.  Methods: In the present study, 30 first-voided
urine (FVU) specimens and 20 urethroglandular swabs using cervex-brushes from male partners of HPV-positive
patients, and 31 FVU specimens and 100 liquid-based cervix cytology leftovers sampled with cervix-brushes from
HPV-positive women were examined for the presence of β-globin.  Oncogenic HPV were detected using type-specific
PCR.  Results: β-globin was found in all the brushed samples, whereas it was found in only 68.9% of the FVU
specimens.  HPV-PCR was positive in 60.0% of the male brushes, in 29% of the female brushes and in 0% of the male
FVU specimens.  DNA concentration was, respectively, 0.9998 ng/μL, 37.0598 ng/μL and 0.0207 ng/μL.  Conclusion:
Urine is not a good tool for HPV detection, probably because the low DNA concentration reflects a low amount of
collected cells.  β-globin is measurable in FVU by real time quantitative PCR, but the DNA concentration is lower
compared to brush sampling for both genders.  β-globin-positivity of urethral and cervical swabs is 100%, showing
a higher mean concentration of DNA, leading to a higher detection rate of HPV.  This is the first article linking DNA-
concentration to the presence of HPV. (Asian J Androl 2007 Sep; 9: 705–710)
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cell suspension was obtained.  From this cell suspension,
400 µL was used to extract DNA, as previously described [5].
2.3  PCR analysis of HPV DNA
First, each sample was subjected to a quantitative
real-time PCR amplification for the detection of β-globin.
This was done to confirm that the DNA quality was still
suitable for PCR analysis.  Only samples that tested posi-
tive for β-globin were tested with the MY 9/11 consen-
sus PCR, and only samples that tested positive for the
consensus PCR were typed for oncogenic HPV types
using type-specific PCR [5].
2.4  Real-time PCR and probe
Oligonucleotide primers were designed with the Primer
Express software (version 1.0; Applied Biosystems, Fos-
ter City, CA, USA).  The probe was designed to ensure a
higher Tm than that for the primers and was manufac-
tured by Applied Biosystems (Cheshire, UK).  The size
of the β-globin PCR product was 167 bp (GenBank Ac-
cession Number U01317).  B-globine-143F 5'-
TGCATTTGACTCCTGAGGAGAA-3', B-globine-223R
5'-GGGCCTCACCACCAACTTC-3', B-globine-167T 5'-
CTGCCGTTACTGCCCT-3'.  β-globin probe was labeled
with 6-carboxyfluorescein at the 5' end and minor groove
binding at the 3' end.
The PCR amplification was performed in a 25 µL
volume containing 2 × TaqMan Universal PCR master
mix (Applied Biosystems, Cheshire, UK), 200 nmol/L
concentration of each primer and probe and 10 µL of
extracted DNA.  Amplification and detection were per-
formed using an ABI Prism 7000 sequence detection
system (Applied Biosystems, Cheshire, UK).  The ampli-
fication conditions were 2 min at 50ºC to activate the
uracil N’-glycosylase, followed by 10 min at 95ºC to
inactivate the uracil N’-glycosylase and release the ac-
tivity of the DNA polymerase, and by a two-step cycle
of 95ºC for 15 s and 60ºC for 60 s for a total of 45 cycles.
2.5  Positive and negative controls for PCR
A tube that contained all PCR components but no
template DNA was used in all runs to ensure that the
reagents were free of contamination.  For the β-globin
real-time PCR a standard curve was obtained by amplifi-
cation of a dilution series of 150 ng to 0.015 ng of fe-
male human DNA (Promega, San Luis Obispo, CA, USA).
2.6  Calculations
whereas high-risk types (16, 18, 31, 33, 45) are related
with anogenital cancer [1].  The most common mem-
bers of the low-risk group and the high-risk group are
HPV 6 and HPV 16, respectively.  Cervical cytology can
detect (pre)malignant lesions in asymptomatic women.
Polymerase chain reaction (PCR) can be used to detect
oncogenic HPV types that are responsible for the de-
tected lesions.  There is no standard screening method
for asymptomatic infected men.  Detection of HPV DNA
in urine could be a screening possibility because screen-
ing kits for other STI are available using PCR-testing of
first-voided urine (FVU) specimens [2].  To evaluate if
HPV-testing on urine is a good technique, β-globin con-
centration and HPV positivity for oncogenic HPV types
are measured using real-time PCR in FVU specimens of
men and women and compared with the findings in swabs
of the glandular urethra and of the glans penis for men
and with swabs of the cervix for women.  Samples are
always checked for β-globin first: the amount of β-globin
is important because it correlates with the amount of
DNA found in the sample.  Furthermore, we looked for a
connection between the amount of DNA and HPV-
positivity.
2    Patients and methods
2.1  HPV testing on FVU
After obtaining informed consent, FVU-specimens
of 30 men and 31 women were processed according to
the Roche Amplicor protocol [3].  All samples tested nega-
tive for Chlamydia trachomatis and Neisseria gonorrhoea
(Roche Amplicor, San Diego, CA, USA).  The rest of the
extracted material was used for HPV-testing by PCR.  DNA
isolation from FVU specimen was performed according
the Roche Amplicor protocol.  The DNA extracts were
stored at –20ºC until PCR was performed.
2.2  HPV on glandular scrape and urethra sampling
Urethro-glandular sampling for men (n = 20) and
cervical sampling for women (n = 100) were performed
using the Cervex-Brush (Rovers, Oss, the Netherlands).
All brush-heads were placed in SurePath vials (Tripath
Imaging, Burlington, NC, USA).  Enriched cell suspen-
sions were obtained by using the fully robotic AutoCyte
PREP System (AutoCyte, Tripath Imaging, Burlington,
NC, USA) [4].  Briefly, vials containing the brush-heads
were vigorously vortexed before transferring on top of a
density gradient.  After centrifugation and washing, a 1-mL
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The threshold cycle number (Ct) was calculated with
Sequence Detection System software (Applied
Biosystems, Cheshire, UK) and an automatic setting of
the baseline (10 standard deviations above the background
in the first 3–15 cycles).  A standard curve was gener-
ated by plotting the Ct values against the log of the amount
of β-globin DNA (in nanograms) and the amount of β-
globin DNA for unknown samples inferred from the re-
gression line.
2.7  Statistical analysis
Comparisons of means were studied by analysis of
variance (ANOVA), followed by the Student–Newman–
Keuls test for all pairwise comparisons.  The χ2-statis-
tics were used to verify the existence of a trend across
ordered groups, such as an increase in HPV positivity.
Statistical tests were considered significant at P < 0.05.
Statistical analysis was performed using the MedCalc
program (MedCalc Software, Mariakerke, Belgium) [6].
3    Results
An overview of β-globin concentrations and HPV
positivity for the different groups is given in Table 1.
The percentage of FVU specimens with detectable β-
globin concentration did not differ between men (66.7%)
and women (71.0%).  In the group where the Cervex-
brush was used to collect urethro-glandular or cervical
cells, β-globin was always detected.  β-globin concen-
tration rises as follows: FVU specimens in men, FVU
specimens in women, Cervex-brush sampling in men,
Cervex-brush sampling in women.  Ultimately, β-globin
concentration in women was 100 times more elevated
than that in FVU specimens of  men.  Although the β-
globin is measurable in FVU specimens by real time quan-
titative PCR, the DNA concentration is lower compared
to Cervex-brush sampling for both men (urethro-
glandular, 100-fold) and women (cervical, 10 000-fold;
Figure 1).  The DNA concentration (ng/µL) is signifi-
cantly higher in the brushes in both men (0.9998 ng/µL)
and women (37.0598 ng/µL) than that in FVU specimens
of men (0.0207 ng/µL) and of women (0.0916 ng/µL)
(ANOVA: P < 0.05).  Oncogenic HPV were detected in
60.0% of the brushes from men and in 28.0% from
women, and in only one sample (3.2%) of the FVU speci-
mens in women and was not detected in FVU specimens
of men.  HPV prevalence is given in Table 2 for each of
the sampling methods.  For men, HPV type 16 was the
most frequently detected HPV, whereas in women HPV
31 was more detected.
4    Discussion
Persistent HPV-infection is a risk factor for anogenital
dysplasia and carcinoma.  Normally, the body clears the
infection in 6–12 months [7], but persistent HPV-load is
maintained in patients with a weakened immunity sys-
tem and by the presence of HPV in the partners’ anogenital
region.  In vitro, the role of sperm as a vector for HPV
has clearly been suggested [8].  HPV prevalence in a
younger population (18–29 years) varies around 33% [9]:
it rises with age and with promiscuity.  Cytological ex-
amination of endocervical smears can detect abnormal
cellular changes in asymptomatic women.  PCR on cer-
vical scrapes is the golden standard to confirm the pres-
ence of HPV.  A satisfactory counterpart does not exist
for asymptomatic men.  Cytological screening of urine
for abnormal cells is not a good diagnostic tool; it cannot
confirm or rule out the presence of visible intraurethral
disease: there is no correlation between cytological ab-
normalities and the presence of HPV-DNA [10].  Urinary
HPV-DNA reflects the presence of infected cells shed
from the epithelium of the urethral meatus.  The amount
of β-globin is an indirect method for measuring these
Table 1.  DNA and human papillomavirus (HPV) content in different sampling methods.  HPV+, positive for oncogenic HPV types (16, 18,
31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 66 and 68); FVU, first-voided urine; Mean conc., mean human DNA concentration. β-globin+,  β-
globin-positivity proves adequacy of the DNA-sample for PCR analysis.
Sampling method    Sex    n     β-globin+    % Mean conc. (ng/µL) HPV+  %
FVU specimens Female   31   22   71.0   0.0916   1   3.2
Male   30   20   66.7   0.0207   0   0
Cervex-brush® Female 100 100 100 37.0598 29 29
Male   20   20 100   0.9998 12 60
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cells.  A low amount of β-globin could result in a lower
HPV detection rate, although approximately 6% is posi-
tive for HPV-DNA while negative for β-Globin [11].  In
these cases HPV-DNA is transferred by desquamated,
anucleated cells, packed with HPV virions.  In the present
study, one of the β-globin-negative-FVU specimens in
the female group was HPV positive.  The number of
HPV copies per infected cell can be as low as one, so a
minimum of infected cells is required to obtain a positive
PCR signal.  The first part of voided urine contains most
of the exfoliated cells; delayed catching of the FVU speci-
mens or collecting a larger amount of urine will adversely
affect the amount of collected cells.  Urine samples can
be stored for 1 week at room temperature without re-
duction of β-globin.  Urinary HPV-detection can be im-
paired by white urea at a concentration of higher than
50 mmol/L, by proteins, or by iron and heparin, all present
in the urine sample.  These inhibitory components can
be removed by boiling the specimen, by phenol-chloro-
form extraction, by diluting or by dialysis, or by pre-
treating the samples with glass beads using GeneClean
(Bio 101, Inc., La Jolla, CA, USA) [12]: all are time con-
suming and generate extra costs.  Logically, the chance
of detecting HPV in urine is higher in cases of intrameatal
warts and lower in patients with genital dermatoses or
warts located outside the urethra [12–14].  Some authors
found additional value in urine testing: Weaver et al. [11]
identified an additional 7% of HPV-DNA positive men.
Others have failed to find HPV in urine.  Laczano et al.
[15] compared urethral swabs and urine samples of 120
sexual active Mexican men, finding detectable β-globin
in respectively 95% and 14% of the samples.  In 43% of
the sample, HPV-DNA was found in penile-urethral swabs,
never in urine.  For women, the results are somewhat
better, probably because of the close proximity of the
urinary tract to the vagina, vulva and cervix [16–21].
We found only one positive HPV 18 sample in FVU of
women.  The women in our study do not have invasive
cervical cancer, so we are unlikely to find many positive
cases.  In Zimbabwe, cervical and urine samples of 43
women with invasive cervical cancer were investigated
for the presence of HPV DNA [18].  HPV was identified
and typed in 98% of cervical swabs and 72% of urine
samples.  Type-specific concordance between cervical
and urine samples was only 79%.  The distance from the
cervix to the sampling spot has an impact on the detec-
Figure 1. DNA concentration and human papillomavirus (HPV) status in different sampling methods. In the Y-axe the concentration of
DNA is given (ng/µL).  In the X-axe the HPV status is given for the different sampling methods.  In all the urine samples the concentration
of DNA is low and no HPV is found.  Only one female urine sample was positive without the finding of DNA.  In the brushed samples the
amount of DNA is higher; also is the number of HPV-positive samples. FVU, first-voided urine.
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tion rate: Sellors et al. [21] noted that the concordance
between cervical specimens and the vaginal, vulva and
urine specimens for the presence of HPV was 0.76, 0.55
and 0.41, respectively.
We would like to evaluate which medium was ap-
propriate for HPV screening in men.  We know from the
published literature that urine is not suitable for cytologi-
cal examination.  Therefore, urine (of both genders) and
male urethral scrapes were tested for β-globin-concen-
tration and HPV-positivity.  We found β-globin in 69%
of the urine samples and in 100% of the brushed samples,
whereas HPV-PCR was positive in 3.2% of the female
FVU specimens, in 0% of the male FVU specimens and
in 60% of the male brushes.  Our results show that for
both men and women, the percentages as well as the
absolute concentration of DNA is significantly lower in
urine (68%) then in swabs taken with the Cervex-brush
(100%).  Despite the encouraging amount of β-globin in
urine, the amount of HPV-DNA is disappointingly low.
We conclude that urine is not the first choice for HPV
screening.  Testing on urine might only be beneficial in
high-risk populations with a high HPV viral load (e.g.
cervical cancer and HIV positive women).  It is not only
crucial to be able to amplify β-globin but also the abso-
lute amount of DNA present is important.  We have shown
for the first time that the amount of human DNA mea-
sured by real-time quantitative PCR is important for HPV
detection in the same sample.
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